CoRISMA, a New Haven CT-based stage medical device company, raised $27M in Series A funding.
The company intends to use the funds to accelerate development and expand availability of the CoRISMA cardiac treatment device.
Led by Mike Theran, Chief Executive Officer, and Pramod Bonde, CoRISMA has advanced a transcatheter that is implanted and features wirelessly powered mechanical circulation support. The company was founded in 2018, spun out of the Bonde Artificial Heart Lab at Yale University.
The round was led by China Grand Pharmaceutical and Healthcare Holdings Limited, which will obtain approximately 22.2% equity interest in the company and broad commercial rights to the Greater China market including Brunei, Greater China (including Mainland China, Hong Kong, Macau, and Taiwan), Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam.
FinSMEs
31/08/2021